ODI Pharma AB: update – missing MAR label in quarterly report
ODI Pharma AB (“ODI” or “the Company”) gives an update regarding that a MAR label was missing in the quarterly report published 28th of May at 15:42 CEST. The updated report – containing a MAR label with reference to the EU´s Market Abuse Regulation – is available as an attached document to this press release and on the company’s website (www.odipharma.com).
For more information on ODI Pharma, please contact:
Derek Simmross, CEO, ODI Pharma AB
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.